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Abstract
Congenital Cytomegalovirus (CMV) infection and alpha 1-antitrypsin (A1AT) deficiency are separately well described entities, but their simultaneous 
occurrence can pose a special challenge to a clinician, especially dealing with optimal diagnostic as well as therapeutic approach. Congenital CMV 
infection is the most common vertically transmitted infection in developed countries. In 85-95% of newborns it runs asymptomatic, while in others 
it is presented with jaundice, petechias, hepatosplenomegaly and central nervous system damage. A1AT deficiency is on the other hand, the most 
common genetic liver disease in children, and the clinical spectrum varies from the accidentally detected increased levels of transaminases through 
to the severe infant cholestasis that can progress to cirrhosis. The following case report describes a two-month old male with severe clinical pre-
sentation of congenital CMV infection probably exacerbated due to A1AT deficiency comorbidity. The clinical manifestations and unusually difficult 
clinical signs this infant presented lead to assumption that the additional liver damage exists. Extensive laboratory analyses were performed, inclu-
ding PCR for CMV DNA, A1AT serum concentration, A1AT genotyping, followed and confirmed with phenotyping. Patient was treated parenteral with 
ganciclovir, what continued with oral valganciclovir and supportive therapy. Intensive and thorough supportive treatment of the infant resulted 
in satisfactory progress and excellent outcome. Patient was followed-up till the age of 18 months. The presented case provides excellent example 
about successful overcoming obstacles in differential diagnosis of A1AT in neonates and infants. Medical charts analysis was the methodology used 
in making this report.
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Cytomegalovirus (CMV) is a ubiquitous virus from 
the Herpesviridae family (1,2). The human CMV ge-
nome consists of a doublestranded DNA with ap-
proximately 230,000 bp (3). CMV is the most com-
mon cause of congenital infection in the devel-
oped world, occurring in ~1% of all liveborns 
(2,4,5). In 85-95% of newborns CMV infection runs 
asymptomatic, while in others it is presented with 
intrauterine growth restriction, microcephaly, 
hearing impairment, thrombocytopenia, anemia, 
jaundice, petechial rash, hepatosplenomegaly and 
central nervous system damage (1,2,4-6). Infants 
with symptomatic congenital CMV infection often 
have dramatic presentations, with a mortality rate 
of 10-30% (1,2,4,6). Infection in fetus/newborn can 
occur during primo-infection of mother, but also 
during reactivation of chronic latent infection and 
as a consequence of reinfection of seropositive 
mother (2,4). Infants born to mothers with primary 
CMV infection during pregnancy are more likely to 
have symptoms at birth (1). Treatment with ganci-
clovir/valganciclovir has to be considered for all 
children with symptomatic infection/disease, pre-
liminary data have shown ganciclovir is effective in 
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the treatment of symptomatic congenital CMV in-
fection (2,5).
Alpha 1-antitrypsin (A1AT) deficiency is considered 
as the most common genetic liver disease in chil-
dren (7). The gene encoding for A1AT is mapped 
on the chromosome 14 (8-10). A1AT, also referred 
to as alpha 1-proteinase (or protease) inhibitor (al-
pha 1-PI) is a 52 kDa, glycoprotein mostly secreted 
by hepatocytes and, to a lesser extent, by lung ep-
ithelial cells and phagocytes (8-11). It belongs to 
the family of serpins (serine protease inhibitors) 
and primarily neutralizes excessive proteolytic ac-
tivity of neutrophil elastase. The altered conforma-
tion of the proteins encoded by the mutated alle-
les makes them prone to intensive intracellular ac-
cumulation or/and degradation in hepatocytes. 
A1AT deficiency is characterized by reduced serum 
A1AT level and/or impairment of A1AT protein. It is 
a common cause of neonatal cholestasis, hepatitis 
in neonates, childhood and adulthood and em-
physema with or without hepatitis in adulthood 
(11-13). Numerous genetic variants of A1AT have 
been noted (14). Majority (95%) of numerous alle-
les of the A1AT gene, are termed as functional, re-
flecting their association with the synthesis if func-
tional A1AT protein, while the remaining 5% are 
jointly named deficiency associated alleles. Ac-
cording to the frequency, they are classified as 
common (Z and S) and rare (Mmalton, null alleles 
etc.) (10,15). The most common phenotype is PiMM 
and is associated with normal levels of A1AT in se-
rum. The two most common deficiency alleles are 
S and Z with S allele producing moderately low 
and Z allele very low levels of A1AT (8-10). In PiZZ 
phenotype serum A1AT concentration is character-
istically reduced to 15% and in PiSS phenotype to 
60% of normal levels. However, A1AT concentra-
tion can raise many folds upon inflammation, thus 
clinical manifestations among A1AT deficiency pa-
tients are under strong influence of environmental 
disease modifiers. An amount below the serum 
protective threshold increases risk for emphysema 
(16). For adults, the recommended consensus ref-
erence interval is 0.9 to 2.0 g/L for individuals with 
PiMM phenotype, with a median of approximately 
1.3 g/L (14). AAT concentrations in PiZZ genotypes 
usually are 0.1 to 0.5 g/L (14). The concentrations 
and the variants are codominant; therefore an in-
dividual with PiMZ, for example would have a con-
centration of approximately 58% of the normal 
PiMM concentration [(100 + 15) / 2] (14). Neonates 
have higher concentrations, possibly because of 
maternal estrogen (14). AAT levels in children are 
lower than those in the adult population (17). Indi-
viduals with concentrations below 0.70 g/L should 
be phenotyped or genotyped, especially if they or 
family members have disease that may be associ-
ated with A1AT deficiency (14).
The production of defective A1AT protein leads to 
a decreased protective activity in the blood and 
lungs on one hand, while deposition of excessive 
abnormal A1AT protein in liver cells results in hepa-
tocyte damage, on the other. The clinical spectrum 
of liver disease is very diverse; it ranges from the 
accidentally detected increased levels of transami-
nases through to severe infant cholestasis that can 
progress to cirrhosis. A1AT deficiency clinical mani-
festations develop as the result of interplay be-
tween mutations in A1AT gene and numerous in-
herited and acquired factors (i.e. smoking, air pol-
lution, comorbidities, especially viral infections) 
(16,18).
According to available literature sources the cur-
rent approach to specific therapy for individuals 
with lung disease related to A1AT deficiency in-
volves administration of the normal A1AT protein 
(8). A1AT augmentatation is recommended only in 
affected patients functionally confirmed emphy-
sema and homozygous presence of Z or rare allele, 
or their heterozygous combination. For those with 
no emphysema developed, the supportive thera-
py and preventive measures are considered suffi-
cient. On the contrary, if the liver is affected, aug-
mentation is not applicable and may even be del-
eterious. Nevertheless, effective supportive meas-
ures are included in therapeutic regimen intended 
for patients with liver damage (18). Therapeutic 
measures include nonspecific or supportive meas-
ures for clinical manifestations of liver and lung 
disease (8). In severe cases of liver or lung disease, 
transplantation has been used successfully in se-
lected cases (8).
Both entities, congenital CMV infection and A1AT 
deficiency, are separately well described, but if 
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they occur simultaneously their management can 
produce diagnostic and treatment challenges. Re-
cently, case report concerning difficulties in misdi-
agnosing has been released (19). In this paper we 
describe a case of a male infant with unusually se-
vere clinical course of congenital CMV infection 
presented by signs of early neonatal liver failure. 
Beside, the clinical manifestations of CMV infection 
in newborns include liver damage, unusually diffi-
cult clinical signs lead to assumption the addition-
al liver damage exists. Raised suspicion on the un-
derlying liver disease was verified by diagnosing 
A1AT deficiency. Clinical Hospital Centre Sestre mi-
losrdnice (CHCSM) Ethics Committee approval has 
been obtained for writing this article.
Case report
A male two-month old infant was admitted for the 
first time to the Department of Paediatric Gastro-
enterology and Hepatology, CHCSM, for liver diag-
nostic work-up under suspicion of a congenital liv-
er disease underlying severe clinical presentation 
of previously established CMV infection. The pa-
tient and his family members were Caucasians. 
The patient’s sister (5.5 years) suffered from spond-
ylo-meta-epiphyseal dysplasia, and other family 
members were healthy. The patient was born from 
the second pregnancy and normal delivery, body 
weight (BW) 2910 g, body length (BL) 49 cm and 
APGAR 10/10. On the second day of life he present-
ed with jaundice and petechial haemorrhages of 
the skin and was admitted to the Neonatology De-
partment in another hospital. Laboratory tests re-
vealed hypoglycaemia, thrombocytopenia, conju-
gated hyperbilirubinemia, hypoalbuminemia, in-
creased activities of aspartate aminotransferase 
and alanine aminotransferase and significantly 
prolonged prothrombine time, whereas the activi-
ty of the gamma-glutamyltransferase was in the 
reference interval (Table 1). The multisliced com-
puterized tomography (MSCT) (Siemens Somatom 
Emotion 2-sliced, Germany) revealed a choledoch-
al cyst type I or II. Abdominal magnetic resonance 
imaging (MRI) (Siemens MAGNETOM Harmony 1T, 
Germany) revealed more voluminous cholecyst, 
medially elongated, and no other formations of 
the cystic contents. Intrahepatic bile ducts were 
not dilated, and extrahepatic bile ducts have failed 
to show up. Brain ultrasound (USD) (Siemens Sono-
 Reference values NICU UHID CHCSM CHCSM-Follow-up
Age 1 day 5 days 2 months 18 months
Glucose (mmol/L)
1.7–3.3 (< 3 days)
2.2–3.3 (> 3 days)
2.8–5.0 (2 weeks - 1 year)
0.3 1.1 2.3 NA
Thrombocytes (x 109/L) 150-450 (1 day - 7 years) 50 66 326 375
Serum total bilirubin (μmol/L) < 86 (< 1 month)< 20 (1 month - 7 years) 482 468 105.8 9.8
Serum conjugated bilirubin (μmol/L) < 10 (< 1 month)< 3 (5 - 19 years) 235 156 46.3 1.4
Serum albumin (g/L) 26-43 (1 - 30 days)28-48 (1 month - 7 years) 19 26 43 50
Aspartate aminotransferase (U/L) 26-75 (0 - 2 years) 199 119 224 143
Alanine aminotransferase (U/L) 11-46 (0 - 2 years) 47 43 127 162
Gamma-glutamyltransferase (U/L) 15-132 (< 3 months)1-39 (3 months - 1 year) 27 14 152 21
Prothrombine time (%) ≥70 10 20 114 94
NICU - Neonatal Intensive Care Unit; UHID - University Hospital for Infectious Diseases; CHCSM - Clinical Hospital Centre Sestre 
milosrdnice.
Table 1. Laboratory tests during follow-up period.
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line G 40 TM) and Hearing Screening (OAE) were 
normal.
Augmentation [fresh frozen plasma (FFP) 15 mL/kg 
and 5% albumin 5 mL/kg] and antimicrobial thera-
py comprising ampicilin (100 mg/kg) and gen-
tamycin (3 mg/kg) combination were initiated, ac-
companied with combined parenteral and enteral 
feeding due to a poorly tolerated oral intake of 
amino-acid based infant formula. Because the 
findings were suggestive of perinatal liver failure 
the patient was transferred to the Neonatal Inten-
sive Care Unit (NICU), and later the same day 
moved to the University Hospital for Infectious 
Diseases (UHID) due to positive PCR for CMV DNA 
(CMV real-time PCR assay; Cepheid, CA, USA), both 
in blood (452 copies/mL) and urine (393 4210 cop-
ies/mL), but not in the cerebrospinal fluid. Samples 
for PCR for CMV DNA were taken during hospitali-
sation in NICU, and laboratory diagnostics per-
formed at UHID. Upon admission to UHID parenter-
al treatment with ganciclovir along with sympto-
matic and supportive measures was introduced. 
Initially, despite daily transfusions of FFP (20 mL/
kg/day prepared by standard procedures of re-
sponsible manufacturer, Croatian Institute for Tran-
sfusion Medicine), vitamin K (0.03 mg/kg/day), pro-
thrombin complex concentrate, a mixture of clot-
ting factors II, VII, IX, X and protein C and S (Octa-
plex, Octapharma Austria) at a dose of 4 mL (100 
Units) during four consecutive days and anti-
thrombin III (Antithrombin III Immuno, Baxter, USA) 
at a dose of 300 Units/daily (six doses cumulative-
ly), coagulation parameters remained low, al-
though visible bleeding was not recorded. Conju-
gated hyperbilirubinemia persisted, and at dis-
charge serum total bilirubin was 205.8, direct 78 
μmol/L. Only after four weeks (5th week of life) a 
graduate normalization of coagulation factors and 
platelets occurred. Hospitalization was complicat-
ed by catheter-related sepsis caused by Methicil-
lin-resistant Staphylococcus aureus (MRSA), which 
has been treated with vancomycin (45 mg/kg) for 
14 days with good response, and mild flow rotavi-
rus gastroenteritis (real-time PCR method) treated 
with standard hypoosmolar oral rehydration solu-
tion. Parenteral treatment with ganciclovir (at a 
dose of 2 x 6 mg/kg/daily) was carried out on daily 
basis during 3 weeks and continued with oral 
treatment with valganciclovir (at a dose of 2 x 18 
mg/kg/day) until CMV PCR DNA analysis from 
blood negativization at the age of 3 months. Oral 
intake (standard infant formula) was gradually in-
troduced and increased with initially good start in 
weight gain, but at the end weight become stag-
nant. Psychomotor development was satisfactory. 
Presence of the infection with other hepatotrophic 
viruses [Hepatitis A virus (HAV), Hepatitis B virus 
(HBV), Hepatitis C virus (HCV), Epstein–Barr virus 
(EBV)] was tested; Anti-HAV total (IgM/IgG), Anti-
HAV IgM, HBsAg, anti-HBs, total anti-HBc, IgM anti-
HBc, HBeAg, anti-HBe, DiaSorin, Italy; HCV Ag-Ab, 
Bio-Rad, France; HCV confirmation test immunob-
lot/western blot, Innogenetics, Belgium; however 
only positive was PCR for CMV DNA. The infant was 
vaccinated with ENGERIX-B [Hepatitis B Vaccine 
(Recombinant)] GlaxoSmithKline, while vaccine 
against tuberculosis BCG was not administered.
At the age of 2 months the patient was transferred 
to the Department of Paediatric Gastroenterology 
and Hepatology, CHCSM for further liver work-up. 
At admission was in good general condition, 54.5 
cm length [13th centile (c)], 4200 g weight (11th c; 
BMI 14.4 kg/m2), and head circumference was 40 
cm (76th c). Skin and sclera were icteric, with no 
signs of rash or bleeding, decreased fat tissue es-
pecially on the limbs, normal bone and joint sys-
tems. Milder abdominal distension with soft liver 
palpable for 2 cm and spleen palpable for 1 cm 
was present. There were no signs of peripheral 
oedema or deformity. Neurological status was 
mildly hypotonic, in accordance with age.
Laboratory testing revealed reduced A1AT serum 
concentration (0.2-0.3, reference values 0.9-2.0 g/L), 
which was an important cooperative factor appar-
ently necessary for the development of unusually 
severe clinical presentation in the first days of life 
with signs of liver failure. Due to a decreased A1AT 
serum concentration, for the child and his parents 
A1AT genotyping was performed by using Light-
Cycler® 480 II (Roche Diagnostics Deutschland 
GmbH, Mannheim, Germany) real-time PCR meth-
od (LightMix® Kit Alpha1-Antitrypsin (AAT) Pi*S 
and Pi*Z, TIB MOLBIOL GmbH, Berlin, Germany). 
Genotyping was followed and confirmed with 
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phenotyping (isoelectric focusing method fol-
lowed by immunofixation on precasted agarose 
gel; semi-automated method on HYDRASYS Fo-
cusing system, Sebia, France), as it is our standard 
protocol for low A1AT serum values. The combina-
tion of genotyping and quantification, with a re-
flex to phenotyping, is the optimal strategy for the 
laboratory evaluation of A1AT deficiency (20,21). 
Genotype/phenotype results were concordant to 
each other: PiZZ phenotype for the child and PiMZ 
phenotype for both parents (mother A1AT serum 
concentration was 0.73, and father 0.71 g/L). A1AT 
genotyping was in concordance with phenotypes. 
Sweat test for cystic fibrosis screening, faecal 
elastase as well as thyroid hormone levels were 
normal. Abdominal USD (Siemens Sonoline G 40 
TM, Germany) was unremarkable. Technetium 
99m-hepatic iminodiacetic acid (HIDA) (Siemens 
Symbia T Germany) scintigraphy confirmed signifi-
cant intrahepatic cholestasis with normal gallblad-
der function and the preserved passage into the 
intestine. Electrocardiographic and heart ultra-
sound (Siemens Sonoline G 40 TM) finding was 
normal. There were no signs that would raise sus-
picion of Alagille syndrome (22).
Therapy with ursodeoxycholic acid (UDCA; 10 mg/
kg/daily), fat-soluble vitamin supplementation and 
medium-chain triglycerides (MCT) oil in meals was 
introduced along with hypercaloric feeding. UDCA 
may significantly improve clinical status and liver 
test results in some children with liver disease as-
sociated with PiZZ A1AT deficiency (23). High dos-
es of vitamin D3 and other liposolubile vitamins 
(A, E, K) reimbursement continued as well as thera-
py with valganciclovir till the age of 3 months 
when CMV PCR DNA analysis from blood was neg-
ative. Coagulation parameters were corrected by 
daily FFP transfusions, vitamin K, prothrombin 
complex and antithrombin III supplementation. 
There was no need for vitamin K parenteral appli-
cation. Hypercaloric diet (120% of the average dai-
ly caloric requirement) with extensively hydrolysed 
infant formula due to the higher MCT concentra-
tion was introduced and well tolerated.
Early introduced antiviral therapy and persistent 
supportive therapy in the first weeks of life bridged 
severe coagulation disorder, as well as hypoalbu-
minemia which were accompanied by all the ex-
pected consequences. In the further course liver 
disease was biochemically characterized by signs 
of moderate cholestasis with slowly but complete-
ly normalized synthetic and metabolic function. 
Despite the above mentioned events, the infant`s 
progress, somatic and psychomotor, was satisfac-
tory. Within CMV infection there were no signs of 
the central nervous system impairment.
During the entire hospitalisation the patient was 
in good general condition, afebrile, vigorously cry-
ing, interestedly observing the surroundings, with 
good appetite and normal stools. He was dis-
charged at the age of three months with a satisfac-
tory weight gain (4750 g; 15th c) as well as somatic 
and motoric progress. Despite the high serum con-
centrations of bile acids (267.8; reference values < 
10 µmol/L) there were no signs of pruritus.
The clinical course in the following 15 months 
showed excellent physical condition with normal 
weight gain and psychomotor development. At 
home, he was fed with frequent meals of exten-
sively hydrolysed infant formula thickened with 
rice cereal and MCT oil added. The introduction of 
normal food was started at the age of 6 months. 
Vitamin D3 and multivitamin drops with docosa-
hexaenoic acid (DHA) mL was continued and 
UDCA slowly tapering in accordance with the nor-
malization of the liver function tests. At the age of 
18 months, laboratory testing revealed no signs of 
cholestasys with normal values of serum bilirubin 
levels, bile acids (2.3 µmol/L) and vitamin D3 (170; 
reference values ≥ 75 nmol/L) levels, but with per-
sistent signs of moderate hepatocellular lesion (Ta-
ble 1).
Discussion
There is limited number of similar cases in the lite-
rature. Related cases report either CMV infection 
or A1AT deficiency, however not presented in same 
patient (5,7,13). There has been report of comorbid 
presentation of A1AT deficiency and CMV infection 
in adult (24). Additionally, one reported case pre-
sented 2-month infant, PiMM phenotype with uri-
nary CMV, but without signs of hepatic necrosis, 
infection or cirrhosis (25). In our hospital the first 
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case of A1AT deficiency was described in 1977, and 
one severe of PiZZ phenotype in 2007 (13,26). It 
was not associated with any other disease, such in 
this exceptional case (13). In our hospital this is the 
first case of such comorbidity presentation. The 
presented case provides excellent example about 
successful overcoming obstacles in differential di-
agnosis of A1AT in neonates and infants, as sug-
gested by previous review (18). A simultaneously 
coexisting CMV infection and A1AT deficiency trig-
gered severe clinical presentation. In this unique 
case, the underlying A1AT deficiency was en-
hanced by CMV infection. A1AT concentration can 
raise many folds upon inflammation. Clinical mani-
festations among PiZZ phenotype patients are un-
der strong influence of environmental disease 
modifiers. In certain high risk groups, CMV infec-
tion may be dangerous (6). A1AT deficiency might 
be a relevant feature that predisposed to the se-
vere clinical course of congenital CMV infection in 
this patient and vice versa. A1AT plays an impor-
tant role in modulating immunity, inflammation, 
proteostasis, apoptosis, etc. A1AT has anti-inflam-
matory activities independent of its protease in-
hibitor function. The most frequently noted classi-
cal triad of clinical manifestations of CMV infection 
is jaundice (62%), petechias (58%), and hepat-
osplenomegaly (50%) and CMV infection could be 
disease stimulant in patients with the PiZZ pheno-
type that already are at risk to develop liver injury 
(1,6,12). Collaborative work of Neonatology, Inten-
sive Care Unit, Infectious Diseases and Gastroen-
terology Paediatric Departments as well as special-
ists of laboratory and transfusion medicine, micro-
biologists and radiologists was essential in manag-
ing and resolving this case. Multidisciplinary team-
work was imperative for adding value of this re-
port. Beside routine laboratory tests and imaging 
procedures recommended diagnostic procedures 
that have to be incorporated into routine diagnos-
tic investigation of a child presenting with liver dis-
ease are CMV real-time PCR assay and determina-
tion of A1AT phenotype (1,6,27).
Optimal therapeutic approach was demand to be 
resolved and discussed. Taking into consideration 
severe clinical presentation of disease, an exten-
sive treatment was introduced. Due to intensive 
and thorough supportive treatment during hospi-
talisation, at discharge from hospital and during 
the follow-up period the infant progress was satis-
factory. In case of A1AT deficiency, liver functions 
need to be followed with a possibility to perform 
liver transplantation if considered necessary. Ex-
tensive diagnostic work-up, treatment and team-
work were imperative to give value to this particu-
lar case.
Prevention of the progression of lung diseases (eg. 
asthma, respiratory infection) is the main goal in 
management of subjects with A1AT deficiency. In 
addition, exposure to tobacco and air pollution 
should be avoided; choice of professional career 
may facilitate the main goal. Furthermore, since 
the Z allele is relatively frequent in the Caucasian 
population (about 1 in 50), genetic counselling for 
individuals and families who have diagnosis of 
A1AT deficiency, particularly in complex cases is of 
great importance.
Conclusion
The paper describes challenges in diagnosis and 
treatment of congenital CMV infection and A1AT 
deficiency which, in case of comorbidity, can 
present with a severe clinical course. There was 
obvious a relation between CMV infection and 
A1AT deficiency observed in our case. Their coex-
istence produced the expression of severe clinical 
presentation that emphasized the importance of 
CMV real-time PCR assay and A1AT phenotyping as 
part of routine diagnostic evaluation when deal-
ing with liver dysfunction in infancy. It remains a 
challenge for further researchers as well as clini-
cians to investigate possible diagnostic and treat-
ment correlations between these two well-known 
diseases.
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